Artificial Intelligence
Why rare diseases are a proving ground for medical innovation
Rare diseases drive breakthrough medical innovation, but unlocking their full impact depends on better data, policy alignment and global collaboration
Elizabeth Hampson
Elizabeth is a Life Sciences and Health Innovation Partner at Deloitte Consulting and the leader of the European Deloitte Health Institute. In this capacity, she plays a pivotal role in creating value from health innovation, accelerating patient access, and improving health outcomes for all. Elizabeth is a firm believer that collaboration is the key to a better Future of Health, and she has dedicated over two decades to convening and advising public and private sector organisations across the health ecosystem, including governments, innovators, investors, and NGOs.
Before her current role, Elizabeth's career began in investment advisory at Goldman Sachs and UBS, where she advised institutional investors and developed her foundational interest in responsible business.
With over 20 years of experience, Elizabeth is a frequent speaker on critical topics such as access to innovation, prevention, equity, employee, and mental health. Her extensive project experience includes advising central and local governments on Life Sciences policy, including access to innovation, pricing, and future health trends. She has also guided major Life Sciences organisations on commercial strategy, government affairs, medical affairs, and market access, and supported major charities and NGOs with their health and innovation strategies. Notably, Elizabeth supported the UK Government in developing health and life science policy, including the prevention element of the NHS 10-year plan, and launched the impactful "economic value of prevention report," highlighting prevention as an economic and social necessity. She has also worked with digital health, med tech, and diagnostics businesses on strategy and innovation.
Elizabeth leads the European Health Equity Institute and is a strategy Partner at the intersection of health and life sciences. She served as a Trustee on the board of a leading European Patient Experience charity for six years and now chairs the Research Advisory Group for a Mental Health charity. Elizabeth regularly publishes on health equity and related topics and is currently supporting the World Economic Forum on the development of place-based change programmes and the Rare Diseases Affinity Group.
Most Popular